logo-loader
viewArc Minerals Limited

UPDATE - Ortac Resources reveals encouraging exploration results from Eritrea

africa_topographical_map_350_5371c46ba5c3a.jpg

---ADDS BROKER COMMENT AND SHARE PRICE---

Ortac Resources (LON:OTC) has revealed encouraging assay results from drilling and trenching at the Yacob Dewar prospect in Eritrea.

The findings confirm that high grade copper exists to the base of oxidation within the core zone of the known mineralisation, the company said.

In a drill hole, mineralisation with 1.11% copper was encountered from surface, whilst gold grades of 1.84 grams per tonne across 24 metres were observed via surface trenching. 

Overall trenching unearthed gold grades up to 4.38 grams per tonne.

Ortac chief executive Vassilios Carellas described the exploration results as ‘excellent’.

"We are encouraged by the second batch of assay results which demonstrate that the copper mineralisation within the core of the deposit, continues to the south and remains strongly mineralised with excellent grades across broad intersections,” Carellas said.

"We have now begun to define the eastern and western extents of the mineralisation where the core of the deposit remains open to the north and south.

“The trench results at both Yacob Dewar and Ber Gebey are significant and encouraging.”

Cantor Fitgerald's mining analyst Asa Bridle rates Ortac shares a 'buy' and said: "Results from the Eritrean exploration project continue to be highly encouraging for both near surface copper and gold mineralisation."

He said that with more results to come, the broker was repeating its 'buy' stance and target price of 5.5p.

Shares advanced on Tuesday following the news and are up 5% to 0.21p.

Quick facts: Arc Minerals Limited

Price: 2.95 GBX

AIM:ARCM
Market: AIM
Market Cap: £21.77 m
Follow

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

FOR OUR FULL DISCLAIMER CLICK HERE

Watch

Full interview: Revenue guidance from OptiBiotix as it eyes NASDAQ listing

OptiBiotix Health (LON:OPTI) provides a commercial progress update, explaining why in their financials some items are separated. CEO Stephen O'Hara tells Proactive London what's behind his thinking adding that Optibiotix hopes to reach profitability in 2020. News here too on Sweetbiotix and...

1 day, 17 hours ago

2 min read